The treatment was found to lead to prolonged (29–149 months) and complete symptom- and treatment-free (CSR) remission in 7 MG patients (i.e. six AChR-positive; one negative for anti-AChR antibodies with unknown anti-MuSK and -LRP4 autoantibody status) (79). Here, LRP4 is linked to myasthenia gravis.